Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Evommune › T. Rowe Price Associates, Inc. cut its EVMN stake below 5% (2.3%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000080255-26-000727
Data quality Verified: identifiers matched exactly
Around the same time Insider filing
Traded Nov 13 · filed 4 days later
Not classified as an open-market trade.
Insider filing
Traded Nov 13 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 13 · filed 4 days later
Not classified as an open-market trade.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 6, 2026 Company filing · Form 8-K · Results Reported its results What came next Nov 4, 2026 Company filing · Form 8-K · Material agreement, Unregistered shares Signed an important agreement, and sold new shares without registering them (and 2 more items) Nov 10, 2026 5% stake RA Capital Management, L.P. filed an activist stake (13D) of 8.5% Nov 12, 2026 Company filing · Form 8-K · Results, Reg FD Reported its results, and shared information with investors Nov 16, 2026 5% stake T. Rowe Price Associates, Inc. reported a passive stake (13G) of 2.3% Nov 16, 2026 5% stake Point72 Asset Management, L.P. reported a passive stake (13G) of 6.7% Nov 17, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On November 13, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Evommune, Inc. (the “Company”) approved the entry of an amendment to the applicable employment agreement(s) (each an “Amendment”) with certain executive officers of the Company, including the Chief Executive Officer, the Chief Financial Officer, and the Chief Business & Legal Officer, pursuant to which,…”